TScan Therapeutics, Inc. (TCRX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.34

From 52W high−87.62%

Volume1.14M

Market cap$21.14M

P/E (TTM)—

P/S (TTM)3.0x

Div yield—

Key dataSep 18, 2026

Open

$0.34

From 52W high

−87.62%

Volume

1.14M

Market cap

$21.14M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

21.6

MomentumView details →

1D Return

−6.48%

YTD Return

−68.49%

SummaryUpdated Jun 1, 2026

TScan Therapeutics, Inc. (NASDAQ:TCRX) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Waltham, Massachusetts. The company went public in July 2021 and focuses on developing innovative T cell receptor-engineered T cell therapies for cancer treatment. TScan operates in the emerging field of cellular immunotherapy, specifically targeting both blood cancers and solid tumors through its proprietary T cell engineering platform.

Ask drillr about TScan Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

1.7x

P/S (TTM)

3.0x

P/B (TTM)

0.3x

ProfitabilityView details →

Gross Margin

90.25%

Net Margin

−1655.35%

EBITDA Margin

−1575.60%

ROE (TTM)

−170.55%

ROA (TTM)

−68.66%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

+2.15%

EPS YoY

+16.51%

FCF YoY

+9.76%

Revenue CAGR 3Y

−8.63%

EPS CAGR 3Y

+12.28%

EBITDA YoY

+14.18%

MomentumView details →

1D Return

−6.48%

YTD Return

−68.49%

1Y Return

−82.40%

RSI (14)

21.6

vs 50D SMA

−54.84%

vs 200D SMA

−67.45%

Capital & dividendView details →

Debt/Equity

1.32x

Current Ratio

3.37x

Quick Ratio

3.37x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.23

EPS Surprise

9.23%

Beats (12Q)

8/12

Next Q EPS Est

−$0.25

Avg Surprise (4Q)

15.64%

Rev Surprise

−43.95%

Financials snapshotView financials →

Revenue (TTM)

7.11M

Net Income (TTM)

−117.71M

Op. CF (TTM)

−116.28M

Next earningsNov 11, 2026 →

Latest newsMore news →

TScan Therapeutics, Inc. granted Chief Legal and Strategy Officer Zoran Zdraveski, JD, Ph.D. 1,050,000 restricted stock units effective September 8, 2026.9d ago

TScan Therapeutics, Inc. granted Chief Executive Officer Gavin MacBeath, Ph.D. 2,400,000 restricted stock units effective September 8, 2026.9d ago

Similar companies

Jasper Therapeutics, Inc.JSPR Tvardi Therapeutics, Inc.TVRD Tharimmune, Inc.THAR Atossa Therapeutics, Inc.ATOS GridAI Technologies Corp.GRDX Cellectar Biosciences, Inc.CLRB Find similar companies →

Latest newsMore news →

TScan Therapeutics, Inc. granted Chief Legal and Strategy Officer Zoran Zdraveski, JD, Ph.D. 1,050,000 restricted stock units effective September 8, 2026.9d ago TScan Therapeutics, Inc. granted Chief Executive Officer Gavin MacBeath, Ph.D. 2,400,000 restricted stock units effective September 8, 2026.9d ago TScan Therapeutics terminated CFO Jason A. Amello and CMO Chrystal Louis, effective September 2, 2026, and CEO Gavin MacBeath assumed the additional role of Chief Financial Officer.18d ago